Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Rheumatology Therapeutics Market Size Forecast: How Large Could The Market Become By 2030?
The rheumatology therapeutics market has experienced consistent expansion in recent years. Projections indicate it will rise from $44.18 billion in 2025 to $46.16 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.5%. This historical growth has been driven by factors such as the growing incidence of rheumatoid arthritis and osteoarthritis, broader access to NSAIDs and corticosteroids, enhanced diagnostic capabilities for rheumatic conditions, improved healthcare availability in developed regions, and increased utilization of conventional synthetic DMARDs.
The rheumatology therapeutics market is projected to experience consistent expansion over the coming years. By 2030, its value is anticipated to reach $54.16 billion, reflecting a compound annual growth rate (CAGR) of 4.1%. This forecasted growth is driven by an increased demand for biologic disease-modifying antirheumatic drugs (DMARDs), a growing elderly population suffering from chronic joint conditions, greater emphasis on early diagnosis and treatment, an expansion in the availability of targeted synthetic DMARDs, and higher healthcare spending directed at managing chronic diseases. Key developments shaping this period include a rising uptake of biologic and targeted DMARDs, a transition toward prompt and intensive disease control, more frequent use of combination therapies for rheumatic conditions, a heightened focus on achieving sustained remission, and the broadening of customized treatment strategies within rheumatology.
Download A Free Sample Report For Comprehensive Market Insights:
Rheumatology Therapeutics Market Expansion Supported By Key Demand Factors
A growing number of autoimmune disease cases is anticipated to fuel the expansion of the rheumatology therapeutics market in the near future. An autoimmune disorder occurs when the immune system erroneously attacks and damages the body’s own organs and tissues. This rising incidence stems from an interplay of genetic, environmental, and lifestyle elements, along with heightened awareness and better diagnostic tools. Rheumatology treatments are essential for these conditions to control inflammation, relieve symptoms, and stop joint and tissue harm caused by the body’s immune response. For example, in June 2024, the Australian Institute of Health and Welfare, a government body based in Australia, reported that approximately 514,000 people in Australia—or 2.0% of its population—were estimated to have rheumatoid arthritis in 2022. This disease represented 2.0% of the total disease burden and 16% of the burden for all musculoskeletal conditions in 2023. Consequently, the increasing occurrence of autoimmune diseases is driving the rheumatology therapeutics market.
Rheumatology Therapeutics Market Segment Breakdown: Which Categories Generate The Most Revenue?
The rheumatology therapeutics market covered in this report is segmented –
1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications
Subsegments:
1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs
3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids
4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase
5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics
Rheumatology Therapeutics Market Growth Trends Influencing Competitive Dynamics
Key players in the rheumatology therapeutics market are introducing novel approaches such as intravenous (IV) formulations to improve how well treatments work and make them easier for patients to use. An IV formulation is a type of medication given straight into a vein using a needle or catheter. In October 2023, for example, Switzerland-based pharmaceutical company Novartis AG announced that the US Food and Drug Administration (FDA) had given the green light to Cosentyx as an IV formulation. This version of Cosentyx is the only one of its kind authorized to treat adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It functions by precisely targeting and blocking interleukin-17A (IL-17A) and stands as the sole non-tumor necrosis factor alpha (TNF-a) IV therapy available for these indications.
Rheumatology Therapeutics Market Key Players And Strategic Industry Positioning
Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., UCB S.A., Sanofi SA, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Janssen Biotech, Genentech Inc., Galapagos NV
Access The Complete Rheumatology Therapeutics Market Report:
Rheumatology Therapeutics Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the rheumatology therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model